Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

Inclusion Criteria: All Cohorts * Subjects must meet all of the following criteria to be included in the study: * Male or female, ≥ 40 years of age. * BMI \>18.0 and \<35.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females. * Clinically stable as determined by medical history, physical examination, vital signs, and clinical laboratory evaluation. * Female subjects of non-childbearing potential must be: post-menopausal; or surgically sterile at least 3 months prior to first dosing. * Sexually active female subjects of childbearing potential must be willing to use an acceptable contraceptive method throughout the study as detailed in protocol. * Smoker (no more than 25 cigarettes or equivalent daily) or non-smoker. Obstructive Pulmonary Function Cohort * Subject with a smoking history of at least 10 pack-years. * Subject with an established diagnosis of COPD at least 12 months prior to the screening visit AND confirmed at screening by spirometry, with a post bronchodilator FEV1 greater than 40% and equal to or less than 70% of the subject's normal predicted value and a post-bronchodilator FEV1 greater than 40% and equal to or less than 70% of the subject's normal predicted value and a post-bronchodilator FEV1/ FVC ratio \< 0.70. * Subject on stable uninterrupted maintenance COPD therapy for at least 3 months prior to screening as per SoC and without any history of moderate or severe exacerbations within 6 months prior to screening. * Non-symptomatic subject …